Mobocertinib added in NICE guidelines
NICE guidelines have added the guidance on mobocertinib to the systemic anti-cancer therapy treatment pathways for advanced non-small-cell lung cancer.
They would like your feedback on how the treatment pathways present content from different sources (NICE technology appraisal guidance, guideline recommendations, and expert input). To comment, go to the link below on systemic anti-cancer therapy for advanced non-small-cell lung cancer and fill in the pop-up survey.
Recent Posts
Advancements in Continuous Glucose Monitoring for Type 2 Diabetes Management
Advancements in CGM for Type 2 Diabetes Management
A recent JAMA Insights article, explores the integration of continuous glucose monitoring as a complementary tool to traditional hemoglobin A1c (HbA1c) an...
GLP-1RAs Psychiatric Care: Transforming Metabolic Management for Psychotropic Patients
Emerging Role of GLP-1 Receptor Agonists
In psychiatric care, GLP-1RAs offer a promising approach for managing weight gain induced by psychotropic medications, as detailed in this
NICE Endorses Obecabtagene Autoleucel Therapy for Adult Relapsed B-Cell Leukaemia
NICE Backs Obecabtagene Autoleucel
The National Institute for Health and Care Excellence (NICE) recommended obecabtagene autoleucel therapy, a UK-developed chimeric antigen receptor (CAR) T-cell trea...